Sugi Predict

Sugi Predict / Compounds / SCHEMBL14737720

SCHEMBL14737720

SCHEMBL14737720

CCCC[Sn](CCCC)(CCCC)c1nn(C)c2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 1/20 0.39
▸ RORA P35398 1/20 0.39
▸ RORC P51449 1/20 0.39
▸ RORB Q92753 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ TLR8 Q9NR97 3/20 0.38
▸ SLC9A1 P19634 4/20 0.36
▸ MPO P05164 3/20 0.36
▸ CNR2 P34972 3/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ CNR1 P21554 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ SLC2A1 P11166 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27978948 0.83 PGR (0.35) PGRRORARORCRORBALDH1A1
SCHEMBL14737417 0.81 TLR8 (0.41) PGRRORARORCRORBALDH1A1
SCHEMBL14737562 0.80 MAPK8 (0.42) —
SCHEMBL14738255 0.80 ICMT (0.38) ALDH1A1TLR8CNR2CNR1SMN1; SMN2
SCHEMBL14738694 0.80 MAPK8 (0.37) ALDH1A1CYP1A2
SCHEMBL14738413 0.80 PSEN1 (0.40) PGRRORARORCRORB
SCHEMBL28545129 0.78 PDE4A (0.41) MPOCNR2TDP1L3MBTL1CNR1
SCHEMBL14738488 0.78 GRM4 (0.35) TLR8SLC9A1CNR2CNR1
SCHEMBL14738334 0.77 MAOA (0.42) PGRRORARORCRORBALDH1A1
SCHEMBL14738293 0.77 RORA (0.43) RORARORCRORBCNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106699739-B 3- indoles -4- indazole maleimide compound and its preparation method and application 浙江工业大学上虞研究院有限公司 2019-03-12 — — CN claimed
CN-106699739-A Preparation method and application of 3-indole-4-indazole maleimide compounds 浙江工业大学上虞研究院有限公司 2017-05-24 — — CN claimed
US-11958850-B2 Heteroaryl compounds for kinase inhibition TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-04-16 — — US disclosed
US-20230102829-A1 Heteroaryl Compounds For Kinase Inhibition ARIAD PHARMACEUTICALS, INC. 2023-03-30 — — US disclosed
CN-110526912-B Heteroaryl compounds for kinase inhibition 武田药品工业株式会社 2023-02-14 — — CN disclosed
EP-3778584-A1 PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES ARIAD Pharmaceuticals, Inc. (US) 2021-02-17 — — EP disclosed
EP-3409669-B1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION ARIAD PHARMA INC (US) 2020-10-07 — — EP disclosed
CN-107973785-B Fluorescent probe for detecting silver ions and preparation method and application thereof 浙江工业大学上虞研究院有限公司 2019-12-31 — — CN disclosed
US-20190218212-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION ARIAD PHARMACEUTICALS, INC. 2019-07-18 — — US disclosed
CN-106699739-B 3- indoles -4- indazole maleimide compound and its preparation method and application 浙江工业大学上虞研究院有限公司 2019-03-12 — — CN disclosed
CN-106699739-B 3- indoles -4- indazole maleimide compound and its preparation method and application 浙江工业大学上虞研究院有限公司 2019-03-12 — — CN disclosed
US-20170197962-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION ARIAD PHARMACEUTICALS, INC. 2017-07-13 — — US disclosed
CN-106699739-A Preparation method and application of 3-indole-4-indazole maleimide compounds 浙江工业大学上虞研究院有限公司 2017-05-24 — — CN disclosed
CN-106699739-A Preparation method and application of 3-indole-4-indazole maleimide compounds 浙江工业大学上虞研究院有限公司 2017-05-24 — — CN disclosed
EP-2763990-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2017-02-22 — — EP disclosed
CN-104024258-A Pyrrolopyrazine kinase inhibitors HOFFMANN LA ROCHE 2014-09-03 — — CN disclosed
EP-2763990-A1 PYRROLOPYRAZINE KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-08-13 — — EP disclosed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 — — US disclosed
WO-2013030138-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 — — WO disclosed
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2013-03-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218212-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION ERBB2, EGFR, ERBB3 PGR 511/4885RORA 1344/4885RORC 1203/4885
US-20170197962-A1 HETEROARYL COMPOUNDS FOR KINASE INHIBITION ERBB2, EGFR, ERBB3 PGR 511/4885RORA 1344/4885RORC 1203/4885
US-11958850-B2 Heteroaryl compounds for kinase inhibition ERBB2, EGFR, ERBB3 PGR 511/4885RORA 1344/4885RORC 1203/4885
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS SYK, ZAP70, JAK1 PGR 3257/4885RORA 1952/4885RORC 680/4885
US-20230102829-A1 Heteroaryl Compounds For Kinase Inhibition ERBB2, EGFR, ERBB3 PGR 511/4885RORA 1344/4885RORC 1203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.